Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center

Fineline Cube Jun 23, 2025

The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...

Company Drug

Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval

Fineline Cube Jun 23, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...

Company Drug

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials

Fineline Cube Jun 23, 2025

China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...

Company Drug

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial

Fineline Cube Jun 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial...

Company Deals

United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare

Fineline Cube Jun 23, 2025

United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured...

Company Medical Device

MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry

Fineline Cube Jun 23, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...

Company Deals

Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million

Fineline Cube Jun 23, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...

Company Drug

Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment

Fineline Cube Jun 23, 2025

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...

Company Drug

Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment

Fineline Cube Jun 23, 2025

France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...

Company Drug

Zai Lab’s Partner argenx Secures EU Approval for Vygart in CIDP Treatment

Fineline Cube Jun 23, 2025

China-based Zai Lab Limited’s (NASDAQ: ZLAB, HKG: 9688) Dutch partner argenx SE (NASDAQ: ARGX) announced...

Company Deals

Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager

Fineline Cube Jun 23, 2025

China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...

Company Drug

CanSino Biologics’ PCV13i Vaccine Gains NMPA Approval

Fineline Cube Jun 23, 2025

China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC

Fineline Cube Jun 20, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Company Drug

Wantai Biological Launches Phase III Trial for VZV-7D Varicella Vaccine

Fineline Cube Jun 20, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation of...

Company Drug

MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC

Fineline Cube Jun 20, 2025

Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...

Company Drug

Changchun BCHT Gains NMPA Approval for BK-01 Adjuvanted Influenza Vaccine

Fineline Cube Jun 20, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial...

Company Drug Policy / Regulatory

NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...

Company Deals Drug

Beijing Science Sun Pharma Inks RMB20M Drug Tech Transfer Pact for NeoAB33 Project

Fineline Cube Jun 20, 2025

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...

Posts pagination

1 … 134 135 136 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.